Compare Elanco Animal Health Incorporated Common Stock (ELAN) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Elanco Animal Health Incorporated Common Stock vs Natera Inc. Common Stock — how do they compare? Elanco Animal Health Incorporated Common Stock trades at $22.68 (market cap $11.27B), while Natera Inc. Common Stock trades at $393.27 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 5.1× Elanco Animal Health Incorporated Common Stock's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Elanco Animal Health Incorporated Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Elanco Animal Health Incorporated Common Stock for 6 Days and Natera Inc. Common Stock for 0 Days on average.
| ELAN | NTRA | |
|---|---|---|
Market Cap | $11.27B | $57.03B |
Volume | 4,942,915 | 1,131,157 |
Sector | Health | Health |
52-Week High | $26.84 | $425.64 |
52-Week Low | $19.80 | $179.42 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $14.65B | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ELAN trades at $22.41, down 0.66% today, with a bearish technical signal from moving averages. The company reported a net loss of $232 million in 2025, though revenue grew to $4.72 billion. Recent earnings beats and a 71% analyst buy rating reflect optimism around new product launches like Zenrelia and deleveraging plans discussed at recent conferences.
The outlook hinges on execution of growth initiatives to achieve profitability. Upside exists if new products gain market share as projected, but risks include persistent losses, competitive pressures, and high debt. The consensus price target of $28.00 suggests 25% potential upside from current levels.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Elanco Animal Health Incorporated Common Stock
Elanco develops medicines, vaccines, and other health products for pets and livestock. Its products address prevention and treatment of animal diseases.
Read more on ELAN →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
